Related Content
- Big Molecule WatchSeptember 29, 2023
Regulatory Update on Alvotech’s AVT02, a High-Concentration Interchangeable Adalimumab Biosimilar
- Big Molecule WatchSeptember 29, 2023
FDA Grants Priority Review to Merck’s Application for KEYTRUDA (pembrolizumab) as Part of Treatment for Early-Stage Cervical Cancer
- Big Molecule WatchSeptember 28, 2023
Recent Biosimilar Commercialization Developments
- Big Molecule WatchSeptember 27, 2023
Scheduling Order Issued in REGENXBIO v. Sarepta Litigation
- Big Molecule WatchSeptember 26, 2023
Update on Recent International Biosimilar Approvals
- Big Molecule WatchSeptember 25, 2023
FDA Releases Draft Labeling Guidance for Biosimilar Products
- Big Molecule WatchSeptember 22, 2023
Update on mRNA Vaccine Patent Litigation
- Big Molecule WatchSeptember 15, 2023
Generic and Biosimilar Drugs Save $408B For America’s Patients and Healthcare System in 2022
- Awards and RankingsSeptember 25, 2023
Goodwin Named an LMG Life Sciences Life Cycle Firm for the Twelfth Consecutive Year
- Awards and RankingsOctober 4, 2022
LMG Recognizes Goodwin Lawyers and Practices for Excellence in Life Sciences
- Press ReleaseNovember 17, 2021
Goodwin Releases Update to its Comprehensive Guide to Biosimilars Litigation and Regulation in the U.S.
- Awards and RankingsOctober 26, 2021
Goodwin Named an LMG Life Sciences Life Cycle Firm for the Tenth Consecutive Year
- Press ReleaseJune 28, 2021
Goodwin Adds Life Sciences and Healthcare Litigation Partner William Jackson
- EventsDecember 5, 2020
China's Patent Linkage System: Can Strategies that Work in the U.S. System Be Applied to China?
- Awards and RankingsOctober 5, 2020
Goodwin Named An LMG Life Sciences Life Cycle Firm For The Ninth Consecutive Year
- Speaking EngagementsSeptember 23, 2020
ACI's 11th Summit on Biosimilars & Innovator Biologics